New advances in the biology and treatment of myeloma bone disease
- 1 April 2001
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 38, 15-20
- https://doi.org/10.1016/s0037-1963(01)90090-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Bisphosphonates Act Directly on the Osteoclast to Induce Caspase Cleavage of Mst1 Kinase during ApoptosisJournal of Biological Chemistry, 1999
- A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 1999
- The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen-Containing BisphosphonatesJournal of Bone and Mineral Research, 1999
- Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trialBritish Journal of Haematology, 1998
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998
- Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.Journal of Clinical Oncology, 1998
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myelomaBlood, 1984